Related Experiment Video
Updated: Jul 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Rivaroxaban for Treatment of Left Ventricular Thrombus: A Case Report
Juhaina Salim Al-Maqbali1, Maitha Al-Sibani2, Nasiba Al-Maqrashi3
1Department of Pharmacy, Sultan Qaboos University Hospital, Muscat, Oman.
Direct oral anticoagulants (DOACs) like rivaroxaban may not effectively treat left ventricular thrombus (LVT) in patients with HIV-associated cardiomyopathy. Further randomized trials are needed to confirm DOAC efficacy and safety for LVT treatment.
Area of Science:
- Cardiology
- Hematology
- Infectious Diseases
Background:
- Left ventricular thrombus (LVT) is a serious complication of left ventricular dysfunction and myocardial infarction (MI), increasing the risk of systemic thromboembolism.
- Two-dimensional transthoracic echocardiography (TTE) is the primary diagnostic method for LVT.
- Current FDA-approved treatments include Vitamin K antagonists (VKAs), while direct oral anticoagulants (DOACs) show promise but lack robust clinical trial data.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism I: Introduction

